Volume 20 Issue 7
Jul.  2022
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2022  >  20(7): 1094-1097
DU Li, XU Yuan, ZHANG Lian, XU Gui-hua, WANG Gui-fen, LIU Zhen-jie. Effect of self-designed cancer pain analgesic plaster combined with oxycodone hydrochloride on refractory cancer pain[J]. Chinese Journal of General Practice, 2022, 20(7): 1094-1097. doi: 10.16766/j.cnki.issn.1674-4152.002531
Citation: DU Li, XU Yuan, ZHANG Lian, XU Gui-hua, WANG Gui-fen, LIU Zhen-jie. Effect of self-designed cancer pain analgesic plaster combined with oxycodone hydrochloride on refractory cancer pain[J]. Chinese Journal of General Practice, 2022, 20(7): 1094-1097. doi: 10.16766/j.cnki.issn.1674-4152.002531
shu

Effect of self-designed cancer pain analgesic plaster combined with oxycodone hydrochloride on refractory cancer pain

doi: 10.16766/j.cnki.issn.1674-4152.002531
  • 1.

    Internal Medicine-Oncology, Quzhou Hospital of Traditional Chinese Medicine, Quzhou, Zhejiang 324002, China

Funds:

 81970398

  • Received Date: 2021-10-29
    Available Online: 2022-09-23
    Abstract
  •   Objective  To observe the effect of self-designed external application of cancer pain analgesic plaster combined with oxycodone hydrochloride in the treatment of refractory cancer pain.  Methods  A total of 102 patients with refractory cancer pain admitted to Quzhou Hospital of Traditional Chinese Medicine from January 2019 to June 2020 were selected and divided into the control group and observation group, with 51 cases in each group. The control group was given oxycodone hydrochloride sustained-release tablets, and the observation group was treated with self-designed external application of cancer pain analgesic plaster on the basis of the control group. The clinical pain treatment effect, digital pain score (NRS), dosage of oxycodone, frequency of pain outbreak, average starting time of pain relief, Karnofsky functional status (KPS) score, self-rating anxiety scale (SAS) score and daily sleep time changes were compared. The serum levels of pain-causing mediators and immunoregulatory factors were monitored.  Results  The effective rate of observation group was 93.62%(44/47), which was significantly higher than that of the control group (77.78%, 35/45, P < 0.05). The NRS score of the observation group was significantly lower than that of the control group at 1 day and 1 week after treatment (all P < 0.05). After treatment, compared with the control group, the dose of oxycodone in the observation group was reduced, the number of pain bursts was less and the average time to start pain relief was significantly shortened (all P < 0.05). In the observation group, the KPS score of quality of life significantly increased, the anxiety SAS score was lower, sleep time was significantly increased, the serum pain transmitters SP and PGE2 were significantly decreased and β-EP content significantly increased (all P < 0.05). The IL-2 level in the observation group was significantly higher than that in the control group (all P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).  Conclusion  Self-designed external application of cancer pain analgesia plaster combined with oxycodone hydrochloride in the treatment of refractory cancer pain is safe and effective. Its mechanism may be related to the regulation of serum substance P(SP), prostaglandin E2(PGE2), β-EP and IL-2 levels to relieve pain and enhance immune function.

     

    • FullText(HTML)
  • loading
    • References(22)
  • [1]
    HUNG G, LIU G, ZHOU Z G, et al. Successful treatment of refractory cancer pain and depression with continuous intrathecal administration of dexmedetomidine and morphine: A case report[J]. Pain Ther, 2020, 9(2): 797-804. doi: 10.1007/s40122-020-00183-3
    [2]
    CHEUNG K W A, CHAN P C, LO S H. The use of ketamine in the management of refractory cancer pain in a palliative care unit[J]. Ann Palliat Med, 2020, 9(6): 4478-4489. doi: 10.21037/apm.2019.09.09
    [3]
    RABIA S A, DHARMA N, JESSICA G, et al. A multi-centered case series highlighting the clinical use and dosing of lidocaine and mexiletine for refractory cancer pain[J]. Palliat Care, 2020, 34(2): 90-98.
    [4]
    王凯文, 蒯仂, 金燊懿, 等. 基于中医传承辅助平台的癌痛外敷方用药规律分析[J]. 中国中医基础医学杂志, 2020, 26(2): 254-257. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYJC202002033.htm

    WANG K W, QUAI L, JIN Q Y, et al. External application of cancer pain based on traditional Chinese medicine inheritance auxiliary platform[J]. Chinese journal of basic medicine of traditional Chinese medicine, 2020, 26(2): 254-257. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYJC202002033.htm
    [5]
    胡陵静, 郭婷婷, 叶海英, 等. 中医外治四联梯级疗法治疗癌性疼痛的探讨与应用[J]. 中国中医急症, 2021, 30(1): 105-108. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYJZ202101029.htm

    HU L J, GUO T T, YE H Y, et al. Discussion and application of quadruple cascade therapy in the treatment of cancer pain[J]. Chinese Medical emergenc, 2021, 30(1): 105-108. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYJZ202101029.htm
    [6]
    王昆, 金毅. 难治性癌痛专家共识(2017年版)[J]. 中国肿瘤临床, 2017, 44(16): 787-793. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZL201716001.htm

    WANG K, JIN Y. Expert Consensus on Refractory Cancer Pain (2017 edition)[J]. Chinese Journal of Clinical Oncology, 2017, 44(16): 787-793. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZL201716001.htm
    [7]
    谭冠先, 罗健, 屠伟峰. 癌痛治疗学[M]. 郑州: 河南科学技术出版社, 2019: 201-202.

    TAN G X, LUO J, TU W F. Cancer pain therapy[M]. Zhengzhou: Henan Science and Technology Press, 2019: 201-202.
    [8]
    ZHOU N B, WANG K G, FU Z J. Effect of morphine and a low dose of ketamine on the T cells of patients with refractory cancer pain in vitro[J]. Oncol lett, 2019, 18(4): 4230-4236.
    [9]
    ASHWIN V, ADITYA V, KENNETH R, et al. Minimally invasive cordotomy for refractory cancer pain: A randomized controlled trial[J]. Oncologist, 2019, 24(7): 590-596. doi: 10.1634/theoncologist.2018-0570
    [10]
    陈雨, 林青, 刘传波, 等. 癌性疼痛的中医治疗进展[J]. 医学综述, 2020, 26(20): 4112-4116. doi: 10.3969/j.issn.1006-2084.2020.20.030

    CHEN Y, LIN Q, LIU C B, et al. Progress of traditional Chinese medicine in the treatment of cancer pain[J]. Medical review, 2020, 26(20): 4112-4116. doi: 10.3969/j.issn.1006-2084.2020.20.030
    [11]
    彭筱娴, 张培彤. 从叶天士络病理论探析癌性疼痛治法[J]. 中医学报, 2021, 36(3): 465-468. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZK202103004.htm

    PENG X X, ZHANG P T. Research on the treatment of cancer pain from the theory of ye tianshilu disease[J]. Journal of traditional Chinese medicine, 2021, 36(3): 465-468. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZK202103004.htm
    [12]
    蔡昀方, 刘春喜, 刘信毅, 等. 奥施康定联合氟比洛芬酯治疗中重度肿瘤骨转移患者疼痛的临床观察[J]. 中华全科医学, 2020, 18(7): 1122-1124. doi: 10.16766/j.cnki.issn.1674-4152.001444

    CAI Y F, LIU C X, LIU X Y, et al. Clinical observation of oxyContin combined with flurbiprofen axetil in the treatment of pain in patients with moderate to severe tumor bone metastases[J]. Chinese Journal of General Practice, 2020, 18(7): 1122-1124. doi: 10.16766/j.cnki.issn.1674-4152.001444
    [13]
    齐宏亮, 曲迎春, 尹诗航. 盐酸羟考酮缓释片在老年癌痛患者中的应用效果分析[J]. 癌症进展, 2021, 19(3): 283-285. https://www.cnki.com.cn/Article/CJFDTOTAL-AZJZ202103018.htm

    QI H L, QU Y C, YIN S H. Effect of oxycodone hydrochloride sustained-release tablets in elderly patients with cancer pai[J]. Cancer Progression, 2021, 19(3): 283-285. https://www.cnki.com.cn/Article/CJFDTOTAL-AZJZ202103018.htm
    [14]
    RAGHU S T, RAGHAVENDRA R, ARIF A, et al. Indian Society for Study of Pain, Cancer Pain Special Interest Group guidelines on pharmacological management of cancer pain (part Ⅱ)[J]. Indian J Palliat Care, 2020, 26(2): 180-190. doi: 10.4103/0973-1075.285693
    [15]
    WANG K Y, GU Y, LIAO Y H, et al. PD-1 blockade inhibits osteoclast formation and murine bone cancer pain[J]. J Clin Invest, 2020, 130(7): 3603-3620. doi: 10.1172/JCI133334
    [16]
    YOGESH R, GANGA S, BHAWNA W. Role of intravenous ketamine as adjuvant to opioids in refractory cancer pain: Case report[J]. Nepal J Cancer, 2019, 3(1): 49-53. doi: 10.3126/njc.v3i1.25916
    [17]
    王淑美, 王维, 李配富, 等. 郁消散外敷对癌痛患者β内啡肽和P物质的影响[J]. 中国肿瘤临床与康复, 2018, 25(5): 560-562. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZK201805013.htm

    WANG S M, WANG W, LI P F, et al. Effect of external application of stagnation dissipation on β-endorphin and substance P in patients with cancer pain[J]. Oncology Clinic and Rehabilitation in China, 2018, 25(5): 560-562. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZK201805013.htm
    [18]
    CHONG D, SHAO L, YANG Y, et al. Correlations of cancer pain degree with levels of β-EP, CGRP and PGE2 and the effects of oxycontin on them[J]. J BUON, 2018, 23(5): 1552-1557.
    [19]
    吴盛, 宋益青, 张建军, 等. 补肾祛瘀针刺疗法加穴位注射治疗肺癌骨转移重度癌痛对5-HT、PGE2和ET-1水平的影响[J]. 针灸临床杂志, 2020, 36(11): 5-9. https://www.cnki.com.cn/Article/CJFDTOTAL-ZJLC202011003.htm

    WU S, SONG Y Q, ZHANG J J, et al. Effect of Bushen Quyu acupuncture combined with acupoint injection on the levels of 5-HT, PGE2 and ET-1 in the treatment of severe cancer pain in lung cancer with bone metastases[J]Journal of Acupuncture and Moxibustion, 2020, 36(11): 5-9. https://www.cnki.com.cn/Article/CJFDTOTAL-ZJLC202011003.htm
    [20]
    侯公瑾, 柏正平, 曾普华, 等. 蟾龙镇痛膏对骨转移性癌痛模型大鼠疼痛阈值及血清PGE2、TNF-α、IL-6、β-EP的影响[J]. 中药新药与临床药理, 2019, 30(10): 1222-1227. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXY201910012.htm

    HOU G J, BAI Z P, ZENG P H, et al. Effects of Bufalin analgesic ointment on pain threshold and serum PGE2, TNF-α, IL-6, β-EP in a rat model of bone metastatic cancer pain[J]. Chinese Journal of New Drugs and Clinical Pharmacology, 2019, 30(10): 1222-1227. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXY201910012.htm
    [21]
    徐菊娣, 姜峰, 廖志军, 等. 癌痛患者外周血中致痛因子表达与癌痛的关系[J]. 中国优生与遗传杂志, 2020, 28(12): 1432-1437. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYYA202012004.htm

    XU J D, JIANG F, LIAO Z J, et al. Relationship between the expression of pain-inducing factors in peripheral blood of patients with cancer pain and cancer pain[J]. Chinese Journal of Eugenics and Genetics, 2020, 28(12): 1432-1437. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYYA202012004.htm
    [22]
    王佛有, 赵岩, 周禹辰, 等. 消癌止痛散对小鼠镇痛作用及对血清β-内啡肽、前列腺素E2水平的影响[J]. 中国药物经济学, 2021, 16(3): 115-119. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYWA202103030.htm

    WANG F Y, ZHAO Y, ZHOU Y C, et al. Effects of Xiaoaizhitong Powder on analgesia and serum β-endorphin and prostaglandin E_2 levels in mice[J]. Chinese Journal of Pharmacoeconomics, 2021, 16(3): 115-119. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYWA202103030.htm
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(7)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (187) PDF downloads(6) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return